HEAT BIOLOGICS, INC. Form 8-K March 24, 2016

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 23, 2016

## Heat Biologics, Inc.

(Exact name of registrant as specified in charter)

## **Delaware**

(State or other jurisdiction of incorporation)

001-35994

26-2844103

(Commission File Number)

(IRS Employer Identification No.)

801 Capitola Drive

# Edgar Filing: HEAT BIOLOGICS, INC. - Form 8-K

## Durham, NC 27713

(Address of principal executive offices and zip code)

## (919) 240-7133

(Registrant s telephone number including area code)

#### N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: HEAT BIOLOGICS, INC. - Form 8-K

### Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Heat Biologics, Inc. (the Company) previously reported in a Form 8-K filed on February 23, 2016 with the Securities and Exchange Commission (the SEC) that the Company had received written notice on February 22, 2016 from the NASDAQ Stock Market LLC (Nasdaq) indicating that, as of December 31, 2015 the Company is reported stockholders equity of \$2,495,000 did not meet the \$2,500,000 minimum required to maintain continued listing, as set forth in NASDAQ Listing Rule 5550(b)(1), and that as of February 22, 2016 the Company did not meet the alternatives of market value of listed securities or net income from continuing operations. The Nasdaq notice further stated that pursuant to Nasdaq rules the Company was required to submit to Nasdaq a plan to regain compliance no later than April 7, 2016.

As previously reported in the Company s Form 8-K filed on March 18, 2016 with the SEC, on March 18, 2016, the Company entered into an underwriting agreement with Roth Capital Partners, LLC and Aegis Capital Corp., as representatives of the several underwriters, relating to the issuance and sale of 9,100,000 shares of its common stock, \$0.0002 par value per share (the Common Stock ), and warrants (Warrant ) to purchase up to an aggregate of 6,825,000 shares of its Common Stock, at a combined public offering price of \$0.75 per share and related warrant (the Offering ). The Offering closed on March 23, 2016. The gross proceeds to the Company from the Offering were approximately \$6.8 million, before deducting the underwriting discount and estimated Offering expenses payable by the Company, but excluding the exercise of any Warrants.

As of the date of this report, the Company believes that it has regained compliance with the stockholders equity requirement for continued Nasdaq listing as provided in NASDAQ Listing Rule 5550(b)(1) based upon the proceeds from the Offering completed on March 23, 2016 and the associated increase in the Company s stockholders equity. As of the date of this report, the Company s stockholders equity is in excess of \$2,500,000.

Nasdaq will continue to monitor the Company s ongoing compliance with the stockholders equity requirement and, if at the time of the Company s next periodic report the Company does not evidence compliance, the Company may be subject to delisting.

Edgar Filing: HEAT BIOLOGICS, INC. - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 24, 2016 HEAT BIOLOGICS, INC.

By: /s/ Jeffrey Wolf Name: Jeffrey Wolf

Title: Chairman, President and Chief

**Executive Officer**